Although enrollment was completed at the end of September 2007, three patients with stable disease continue to receive CTCE-9908 therapy. One patient with small bowel carcinoma is now completing the seventh month of therapy, the maximum allowed by the protocol.
Ongoing results of the Phase I/II trial continue to demonstrate that CTCE-9908 is well tolerated with no dose limiting toxicity observed up to the maximum dose of 5mg/kg/day that was tested. The main side effect at the maximum dose tested has been moderate phlebitis (blood vessel inflammation).
The patients enrolled in this study all had terminal cancers with metastatic disease that no longer responded to standard therapy, or for which no curative therapy exists. The company is continuing with its plans to start an international Phase II study in 2008 and is currently seeking to secure funding.
Walter Korz, vice president, drug development at Chemokine, said: “The Phase I/II trial appears to have demonstrated that CTCE-9908 can be delivered for an extended period of time with limited toxicities.”